Phase 1a and 1b results in 3 years time is hardly accelerated...

Phase 1a and 1b results in 3 years time is hardly accelerated development and the $10m will be gone by then (shown in the latest presentation) . So current $35m market value (including the 10m) is hardly going to attract the market speculators and investors. Phase 2 results is what generally gets a share price moving but that wont be until another 4-5years and another $15-20m needed. Plenty of other Biotechs in the phase2/3 field now with real prospects of major returns in the next 12 months such as Neu/Shc/Avh/Ndl/Pab , they are all valued less than $50m but are targeting large markets just like Nrt.